Company
Idorsia Ltd
Headquarters: Allschwil, Switzerland
CEO: Mr. Jean-Paul Clozel M.D.
Market Cap
CHF2.50 Billion
CHF as of Jan. 1, 2023
US$2.70 Billion
Idorsia Ltd Categories
Switzerland
languages
Healthcare
languages
Biotechnology
Switzerland Healthcare
Switzerland Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
Novo Nordisk
|
$304.61 B |
CSL Limited
|
$93.24 B |
Regeneron Pharmaceuticals, Inc.
|
$79.53 B |
| Marinomed Biotech AG | $76.72 B |
|
Vertex Pharmaceuticals Incorporated
|
$74.13 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.